David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Nathan Hale Fowler, MD, of MD Anderson Cancer Center, discusses a multicenter trial in which ibrutinib plus rituximab was administered to treatment-naive patients with follicular lymphoma (Abstract 470).

Leukemia

Julie Vose, MD, MBA

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses a retrospective analysis of data on the overall survival of patients with acute lymphoblastic leukemia when initial therapy is given in academic hospitals vs nonacademic hospitals (Abstract 268).

Leukemia

Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD

Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD on CLL and Venetoclax: Clinical Trial Results

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephan Stilgenbauer, MD, PhD, of the University of Ulm, discuss this late-breaking abstract on venetoclax monotherapy and deep remissions in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion (Abstract LBA6).

Leukemia

Myelodysplastic Syndromes

Mikkael A. Sekeres, MD

Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117

Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses an additional analysis of a phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia (Abstract 908).

Multiple Myeloma

James N. Kochenderfer, MD

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

James N. Kochenderfer, MD, of the National Cancer Institute, discusses a clinical trial of allogeneic T cells expressing an anti-CD19 chimeric antigen receptor, which caused remissions of B-cell cancers after stem cell transplant, without causing graft-vs-host disease (Abstract LBA1).

Apr

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD on CLL and Venetoclax: Clinical Trial Results

Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being